Axogen (NASDAQ:AXGN) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.15) by 60 percent. This is a 33.33 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $34.50 million which beat the analyst consensus estimate of $33.85 million by 1.92 percent. This is a 2.74 percent increase over sales of $33.58 million the same period last year.
Cantor Fitzgerald Reiterates Neutral on TherapeuticsMD, Announces $1 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates TherapeuticsMD (NASDAQ:TXMD) with a Neutral and announces $1 price target.
